CODEXIS, INC.CDXSEarnings & Financial Report
Codexis, Inc. is a protein engineering company that develops enzymes for pharmaceutical, food and medical applications.
Revenue
$8.0M
Gross Profit
$4.5M
Operating Profit
$-22.7M
Net Profit
$-22.8M
Gross Margin
56.6%
Operating Margin
-284.9%
Net Margin
-285.2%
YoY Growth
-62.6%
EPS
$-0.32
CODEXIS, INC. Q2 FY2024 Financial Summary
CODEXIS, INC. reported revenue of $8.0M (down 62.6% YoY) for Q2 FY2024, with a net profit of $-22.8M (down 97.5% YoY) (-285.2% margin). Cost of goods sold was $3.5M, operating expenses totaled $27.2M.
Key Financial Metrics
| Total Revenue | $8.0M |
|---|---|
| Net Profit | $-22.8M |
| Gross Margin | 56.6% |
| Operating Margin | -284.9% |
| Report Period | Q2 FY2024 |
Revenue Breakdown
CODEXIS, INC. Q2 FY2024 revenue of $8.0M breaks down across 2 segments, led by Products at $6.3M (78.4% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Products | $6.3M | 78.4% |
| Researchand Development Revenue | $1.7M | 21.6% |
CODEXIS, INC. Revenue by Segment — Quarterly Trend
CODEXIS, INC. revenue by segment across the last 4 reported quarters, showing how each business line (such as Products and Researchand Development Revenue) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Products | — | $6.8M | $7.4M | $6.1M |
| Researchand Development Revenue | — | $1.8M | $7.9M | — |
CODEXIS, INC. Annual Revenue by Year
CODEXIS, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $70.4M).
| Year | Annual Revenue |
|---|---|
| 2025 | $70.4M |
| 2024 | $59.3M |
| 2023 | $70.1M |
| 2022 | $138.6M |
CODEXIS, INC. Quarterly Revenue & Net Profit History
CODEXIS, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $38.9M | +81.3% | $9.6M | 24.7% |
| Q3 FY2025 | $8.6M | -33.0% | $-19.6M | -228.1% |
| Q2 FY2025 | $15.3M | +92.1% | $-13.3M | -86.6% |
| Q1 FY2025 | $7.5M | -55.8% | $-20.7M | -274.3% |
| Q4 FY2024 | $21.5M | -19.2% | $-10.4M | -48.4% |
| Q3 FY2024 | $12.8M | +38.3% | $-20.6M | -160.8% |
| Q2 FY2024 | $8.0M | -62.6% | $-22.8M | -285.2% |
| Q1 FY2024 | $17.1M | +31.5% | $-11.5M | -67.4% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $17.1M | $8.0M | $12.8M | $21.5M | $7.5M | $15.3M | $8.6M | $38.9M |
| YoY Growth | 31.5% | -62.6% | 38.3% | -19.2% | -55.8% | 92.1% | -33.0% | 81.3% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $149.6M | $132.0M | $148.2M | $149.0M | $128.9M | $138.2M | $124.0M | $147.8M |
| Liabilities | $70.3M | $70.6M | $74.8M | $82.1M | $79.3M | $82.6M | $85.4M | $97.3M |
| Equity | $79.3M | $61.4M | $73.4M | $66.9M | $49.6M | $55.6M | $38.5M | $50.5M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-7.8M | $-12.2M | $-13.0M | $-16.5M | $-13.8M | $-18.0M | $-7.7M | $20.1M |